Sold as Corvert. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 15, 2026, FDA lists 5 applications for Ibutilide Fumarate (sold as Corvert), first approved Dec 28, 1995, with 1 new use approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)Atrial Fibrillation (AF), Atrial Fibrillation Ablation · China National Center for Cardiovascular Diseases | Not applicable | Recruiting | May 22, 2026 |
| Dec 28, 1995 | CorvertNDA 20491 · New molecular entity | Pfizer | 6 | Marketed |
| Jan 11, 2010 | Ibutilide FumarateANDA 90240 | Luitpold | 0 | Discontinued |
| Jan 11, 2010 | Ibutilide FumarateANDA 90643 | Pharmobedient | 0 | Discontinued |
| Jan 11, 2010 | Ibutilide FumarateANDA 90924 | Mylan Institutional | 0 | Discontinued |
| Apr 1, 2024 | Ibutilide FumarateANDA 204146 | Avet Lifesciences | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer